Phase II Study of Immune Checkpoint Blockade with Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Ontology highlight
ABSTRACT: Phase II Study of Immune Checkpoint Blockade with Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
PROVIDER: PRJNA760534 | ENA |
REPOSITORIES: ENA
ACCESS DATA